Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Shock, Septic | 13 | 2021 | 1313 | 2.66 | Why? |
| HLA-DR Antigens | 7 | 2021 | 563 | 2.32 | Why? |
| Interleukin-7 | 4 | 2020 | 148 | 1.72 | Why? |
| Immune Tolerance | 6 | 2020 | 608 | 1.39 | Why? |
| Sepsis | 10 | 2020 | 3517 | 1.32 | Why? |
| Monocytes | 8 | 2021 | 2978 | 1.16 | Why? |
| Flow Cytometry | 5 | 2021 | 2393 | 1.06 | Why? |
| Scavenger Receptors, Class E | 1 | 2021 | 50 | 0.88 | Why? |
| Lymphopenia | 4 | 2020 | 2669 | 0.86 | Why? |
| Immunosenescence | 2 | 2019 | 169 | 0.81 | Why? |
| Myeloid-Derived Suppressor Cells | 2 | 2021 | 316 | 0.81 | Why? |
| Sialic Acid Binding Ig-like Lectin 1 | 1 | 2021 | 156 | 0.80 | Why? |
| Staining and Labeling | 1 | 2019 | 169 | 0.72 | Why? |
| Running | 1 | 2017 | 153 | 0.59 | Why? |
| Receptors, IgG | 1 | 2019 | 578 | 0.58 | Why? |
| TOR Serine-Threonine Kinases | 1 | 2017 | 385 | 0.56 | Why? |
| Leukocytes, Mononuclear | 2 | 2021 | 2115 | 0.53 | Why? |
| Shock | 2 | 2018 | 1868 | 0.52 | Why? |
| Glucose | 1 | 2017 | 573 | 0.49 | Why? |
| Immunophenotyping | 3 | 2017 | 1290 | 0.47 | Why? |
| Immunization | 2 | 2021 | 2019 | 0.47 | Why? |
| Intensive Care Units | 9 | 2021 | 29594 | 0.45 | Why? |
| Blood Specimen Collection | 1 | 2015 | 387 | 0.44 | Why? |
| Leukocytes | 1 | 2017 | 1046 | 0.42 | Why? |
| Lymphohistiocytosis, Hemophagocytic | 1 | 2018 | 800 | 0.40 | Why? |
| T-Lymphocytes | 5 | 2018 | 6670 | 0.40 | Why? |
| Immune System | 3 | 2019 | 1479 | 0.40 | Why? |
| Transportation | 1 | 2015 | 691 | 0.38 | Why? |
| Wounds and Injuries | 2 | 2017 | 1708 | 0.35 | Why? |
| T-Lymphocyte Subsets | 1 | 2015 | 1387 | 0.34 | Why? |
| Immunotherapy | 2 | 2020 | 2421 | 0.34 | Why? |
| Interleukin-10 | 3 | 2018 | 1409 | 0.31 | Why? |
| Antigens, Differentiation, B-Lymphocyte | 2 | 2017 | 54 | 0.30 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.26 | Why? |
| Pneumonia | 2 | 2021 | 5652 | 0.26 | Why? |
| Patient Admission | 1 | 2021 | 5250 | 0.26 | Why? |
| Histocompatibility Antigens Class II | 2 | 2017 | 383 | 0.24 | Why? |
| T-Lymphocytes, Regulatory | 2 | 2018 | 698 | 0.22 | Why? |
| Phenotype | 1 | 2012 | 4037 | 0.22 | Why? |
| Interferon-gamma | 3 | 2021 | 2711 | 0.21 | Why? |
| Transcriptome | 3 | 2018 | 3466 | 0.21 | Why? |
| Biomarkers | 10 | 2021 | 23361 | 0.20 | Why? |
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2021 | 203 | 0.20 | Why? |
| Cytokines | 3 | 2021 | 15010 | 0.20 | Why? |
| Interleukin-7 Receptor alpha Subunit | 1 | 2018 | 13 | 0.20 | Why? |
| Immunoglobulin A | 1 | 2011 | 3567 | 0.20 | Why? |
| Terminal Repeat Sequences | 1 | 2018 | 13 | 0.19 | Why? |
| Lymphocytes | 1 | 2012 | 3056 | 0.19 | Why? |
| Lipopolysaccharides | 3 | 2018 | 848 | 0.19 | Why? |
| Preliminary Data | 1 | 2021 | 457 | 0.19 | Why? |
| Retroelements | 1 | 2018 | 27 | 0.19 | Why? |
| Basophils | 1 | 2018 | 179 | 0.18 | Why? |
| Chalcones | 1 | 2018 | 83 | 0.18 | Why? |
| Glucose Transporter Type 1 | 1 | 2017 | 30 | 0.17 | Why? |
| Critical Illness | 6 | 2021 | 17281 | 0.17 | Why? |
| Oxidative Phosphorylation | 1 | 2017 | 120 | 0.17 | Why? |
| Severe Combined Immunodeficiency | 1 | 2018 | 107 | 0.17 | Why? |
| Specimen Handling | 1 | 2015 | 6190 | 0.17 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.16 | Why? |
| Glycolysis | 1 | 2017 | 208 | 0.16 | Why? |
| Interferon-alpha | 2 | 2021 | 1442 | 0.15 | Why? |
| CD4-Positive T-Lymphocytes | 3 | 2021 | 4545 | 0.15 | Why? |
| Humans | 41 | 2021 | 930598 | 0.15 | Why? |
| Aged | 18 | 2021 | 215776 | 0.15 | Why? |
| Compassionate Use Trials | 1 | 2020 | 632 | 0.15 | Why? |
| Cell Proliferation | 3 | 2017 | 1973 | 0.15 | Why? |
| Pneumonectomy | 1 | 2018 | 278 | 0.15 | Why? |
| Sirolimus | 1 | 2017 | 240 | 0.15 | Why? |
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2017 | 277 | 0.14 | Why? |
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 290 | 0.14 | Why? |
| Adenosine Triphosphate | 1 | 2017 | 294 | 0.14 | Why? |
| Male | 23 | 2021 | 367725 | 0.14 | Why? |
| Lymphocyte Activation | 3 | 2021 | 2742 | 0.14 | Why? |
| RNA, Messenger | 3 | 2017 | 5131 | 0.13 | Why? |
| Cells, Cultured | 4 | 2017 | 5835 | 0.13 | Why? |
| CD8-Positive T-Lymphocytes | 3 | 2021 | 5837 | 0.13 | Why? |
| Immunoglobulin M | 1 | 2011 | 9091 | 0.13 | Why? |
| Energy Metabolism | 1 | 2017 | 451 | 0.12 | Why? |
| Receptors, Immunologic | 1 | 2017 | 555 | 0.12 | Why? |
| B-Lymphocytes | 2 | 2018 | 4418 | 0.12 | Why? |
| Interleukin-17 | 1 | 2017 | 602 | 0.12 | Why? |
| Female | 21 | 2021 | 380317 | 0.12 | Why? |
| Up-Regulation | 1 | 2021 | 2249 | 0.12 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2020 | 861 | 0.12 | Why? |
| Models, Immunological | 1 | 2017 | 727 | 0.12 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.11 | Why? |
| Neutrophils | 2 | 2019 | 5476 | 0.11 | Why? |
| Epigenesis, Genetic | 1 | 2017 | 711 | 0.11 | Why? |
| Burns | 1 | 2017 | 466 | 0.11 | Why? |
| Multiple Organ Failure | 1 | 2021 | 1724 | 0.10 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.10 | Why? |
| Lymphocyte Subsets | 1 | 2017 | 987 | 0.10 | Why? |
| Autophagy | 1 | 2017 | 960 | 0.10 | Why? |
| Dermatitis, Atopic | 1 | 2018 | 714 | 0.10 | Why? |
| Autoantibodies | 1 | 2021 | 2094 | 0.10 | Why? |
| Host-Pathogen Interactions | 2 | 2021 | 11041 | 0.10 | Why? |
| Postoperative Complications | 2 | 2018 | 5861 | 0.10 | Why? |
| Antifungal Agents | 1 | 2020 | 1828 | 0.10 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.09 | Why? |
| Dendritic Cells | 1 | 2017 | 1330 | 0.09 | Why? |
| Protein Kinase Inhibitors | 1 | 2018 | 1585 | 0.09 | Why? |
| Gene Expression | 1 | 2019 | 3332 | 0.09 | Why? |
| Survival Analysis | 2 | 2019 | 7592 | 0.09 | Why? |
| Antigens, CD | 1 | 2013 | 984 | 0.09 | Why? |
| Interferon Type I | 1 | 2021 | 2789 | 0.09 | Why? |
| Adjuvants, Immunologic | 1 | 2017 | 1709 | 0.09 | Why? |
| Membrane Glycoproteins | 1 | 2017 | 2273 | 0.09 | Why? |
| Graft Rejection | 1 | 2018 | 1766 | 0.09 | Why? |
| Apoptosis | 1 | 2017 | 2335 | 0.08 | Why? |
| Prognosis | 3 | 2021 | 32490 | 0.08 | Why? |
| Aged, 80 and over | 8 | 2021 | 88759 | 0.08 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2017 | 2483 | 0.08 | Why? |
| Hydrocortisone | 1 | 2017 | 1790 | 0.08 | Why? |
| Lung Transplantation | 1 | 2018 | 1554 | 0.08 | Why? |
| Case-Control Studies | 3 | 2021 | 17671 | 0.08 | Why? |
| Disease Susceptibility | 1 | 2019 | 4002 | 0.08 | Why? |
| Predictive Value of Tests | 1 | 2021 | 9537 | 0.07 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.07 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.07 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2018 | 2984 | 0.07 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.06 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.06 | Why? |
| Lymphocyte Count | 3 | 2018 | 4758 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.06 | Why? |
| Lung Neoplasms | 1 | 2018 | 3228 | 0.06 | Why? |
| Adult | 13 | 2021 | 244371 | 0.06 | Why? |
| Surgical Procedures, Operative | 1 | 2017 | 2662 | 0.05 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 6653 | 0.05 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.05 | Why? |
| Immunity | 2 | 2021 | 2651 | 0.05 | Why? |
| Zanamivir | 1 | 2018 | 63 | 0.05 | Why? |
| Receptors, Complement 3d | 1 | 2018 | 60 | 0.05 | Why? |
| Clonal Anergy | 1 | 2017 | 11 | 0.05 | Why? |
| Antilymphocyte Serum | 1 | 2018 | 80 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2017 | 6153 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| Cell Degranulation | 1 | 2018 | 130 | 0.04 | Why? |
| Endogenous Retroviruses | 1 | 2018 | 72 | 0.04 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2020 | 10083 | 0.04 | Why? |
| Plant Growth Regulators | 1 | 2017 | 20 | 0.04 | Why? |
| fas Receptor | 1 | 2018 | 85 | 0.04 | Why? |
| Monitoring, Immunologic | 1 | 2018 | 153 | 0.04 | Why? |
| Endothelium | 1 | 2021 | 460 | 0.04 | Why? |
| Cord Blood Stem Cell Transplantation | 1 | 2018 | 143 | 0.04 | Why? |
| Antibodies, Blocking | 1 | 2017 | 174 | 0.04 | Why? |
| Clinical Studies as Topic | 1 | 2017 | 118 | 0.04 | Why? |
| Forkhead Transcription Factors | 1 | 2017 | 231 | 0.04 | Why? |
| Adaptive Immunity | 2 | 2019 | 2585 | 0.04 | Why? |
| Neuraminidase | 1 | 2018 | 289 | 0.04 | Why? |
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 347 | 0.04 | Why? |
| Postoperative Period | 1 | 2018 | 651 | 0.04 | Why? |
| APACHE | 1 | 2018 | 682 | 0.04 | Why? |
| Cohort Studies | 3 | 2018 | 36005 | 0.04 | Why? |
| Interleukin-2 | 1 | 2017 | 443 | 0.04 | Why? |
| Statistics, Nonparametric | 1 | 2018 | 1008 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.04 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.04 | Why? |
| Oseltamivir | 1 | 2018 | 583 | 0.03 | Why? |
| Placebos | 1 | 2017 | 629 | 0.03 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.03 | Why? |
| Gene Expression Regulation | 2 | 2017 | 4020 | 0.03 | Why? |
| Patient Acuity | 1 | 2021 | 1755 | 0.03 | Why? |
| Influenza, Human | 1 | 2018 | 10779 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2021 | 9893 | 0.03 | Why? |
| Vasoconstrictor Agents | 1 | 2017 | 714 | 0.03 | Why? |
| Mutation, Missense | 1 | 2018 | 863 | 0.03 | Why? |
| Organ Dysfunction Scores | 1 | 2018 | 1475 | 0.03 | Why? |
| Belgium | 1 | 2018 | 2064 | 0.03 | Why? |
| Piperidines | 1 | 2018 | 795 | 0.03 | Why? |
| Drug Resistance, Viral | 1 | 2018 | 1083 | 0.03 | Why? |
| Switzerland | 1 | 2018 | 2738 | 0.03 | Why? |
| Immunity, Innate | 2 | 2019 | 6570 | 0.03 | Why? |
| Precision Medicine | 1 | 2019 | 1477 | 0.02 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.02 | Why? |
| Immunomodulation | 1 | 2017 | 1472 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2018 | 3786 | 0.02 | Why? |
| Child, Preschool | 2 | 2021 | 36283 | 0.02 | Why? |
| Child | 3 | 2021 | 70012 | 0.02 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Drug Evaluation, Preclinical | 1 | 2018 | 3347 | 0.02 | Why? |
| Immunoglobulins, Intravenous | 1 | 2018 | 2705 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Models, Molecular | 1 | 2018 | 7616 | 0.02 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.02 | Why? |
| Risk Assessment | 2 | 2018 | 25439 | 0.02 | Why? |
| Computational Biology | 1 | 2018 | 4514 | 0.02 | Why? |
| Hospital Mortality | 2 | 2018 | 22087 | 0.01 | Why? |
| France | 1 | 2018 | 12074 | 0.01 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.01 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.01 | Why? |
| Viral Proteins | 1 | 2018 | 7370 | 0.01 | Why? |
| Risk Factors | 2 | 2019 | 71621 | 0.01 | Why? |
| Asthma | 1 | 2018 | 4383 | 0.01 | Why? |
| Animals | 2 | 2019 | 78931 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 11367 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Infant | 1 | 2021 | 30274 | 0.01 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| Viral Load | 1 | 2018 | 15850 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 13720 | 0.01 | Why? |
| Retrospective Studies | 2 | 2018 | 105322 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Critical Care | 1 | 2018 | 14081 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.01 | Why? |
| Adolescent | 1 | 2021 | 86841 | 0.01 | Why? |
| Lung | 1 | 2018 | 31049 | 0.01 | Why? |
| Antiviral Agents | 1 | 2018 | 41703 | 0.00 | Why? |
Monneret's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(214)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(301)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_